Top Medical News
2 hours ago
Sleep disorders commonly occur in patients with ankylosing spondylitis (AS), particularly those with high disease activity, a study has found. Furthermore, treatment with antitumour necrosis factor (anti-TNF)-α improves sleep quality but not polysomnography parameters.
Pearl Toh, 13 hours ago
Targeting mast cells with imatinib, which inhibits the receptor tyrosine kinase KIT, may decrease airway hyperresponsiveness and improve symptoms in patients with severe, poorly controlled asthma, according to a proof-of-principle clinical trial.
14 hours ago
The risk of respiratory syncytial virus hospitalization (RSVH) and respiratory-related illness hospitalization (RIH) does not significantly differ between the first and second year of life in paediatric patients with haemodynamically significant congenital heart disease (HSCHD), a new study shows.
23 hours ago
Both 2 and 4 percent topical diazepam creams result in substantial improvements in pain and bleeding in chronic anal fissures, a new study shows.
Jackey Suen, Yesterday

The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.

Stephen Padilla, Yesterday
The hypothesis that incretin-based treatment increases all-cause mortality in patients with type 2 diabetes (T2D) does not hold water, according to current evidence of a recent study.
The risk of cardiovascular morbidity is reduced in elderly patients who highly adhere to antihypertensive drug therapy, reports a new study. Furthermore, adherence to antihypertensives also lowers the risk of heart failure and stroke, but not myocardial infarction (MI), and extending to all-cause death.
Special Reports
22 Jun 2017
The University of Science, Malaysia (USM) team, led by Professor Dr Lee Yeong Yeh was recognized for its outstanding research submission that links poor hygiene practices in flood-affected areas to the increased risk in communicable intestinal infections in parts of Malaysia.
30 May 2017
Pain is a multidimensional experience that often requires a combination of various approaches to bring about optimal outcomes. At a recent scientific symposium held during the 7th Association of South-East Asian Pain Societies Congress held in Yangon, Myanmar, Professor Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen trometamol (Ketesse®; A. Menarini) can improve acute pain management.
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
Conference Reports
Audrey Abella, 22 Jun 2017
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Roshini Claire Anthony, 21 Jun 2017

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
21 Jun 2017
Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.
21 Jun 2017
Podcast: Professor Bruce Neal summarizes the key findings of the Canagliflozin Cardiovascular Assessment Study.
21 Jun 2017
Podcast: Dr Carla Greenbaum speaks about the potential clinical impact of identifying individuals at risk of type 1 diabetes.
Pearl Toh, 21 Jun 2017
Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!